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ABSTRACT
ObjectiveToevaluatetheassociationof2008-9seasonal
trivalent inactivated vaccine with cases of influenza
A/H1N1 during the epidemic in Mexico.
Design Frequency matched case-control study.
Setting Specialty hospital in Mexico City, March to May
2009.
Participants 60 patients with laboratory confirmed
influenza A/H1N1 and 180 controls with other diseases
(not influenza-like illness or pneumonia) living in Mexico
City or the State of Mexico and matched for age and
socioeconomic status.
Main outcome measures Odds ratio and effectiveness of
trivalent inactivated vaccine against influenza A/H1N1.
Results Cases were more likely than controls to be
admitted to hospital, undergo invasive mechanical
ventilation, and die. Controls were more likely than cases
to have chronic conditions that conferred a higher risk of
influenza related complications. In the multivariate
model, influenza A/H1N1 was independently associated
with trivalent inactivated vaccine (odds ratio 0.27, 95%
confidence interval 0.11 to 0.66) and underlying
conditions (0.15, 0.08 to 0.30). Vaccine effectiveness
was 73% (95% confidence interval 34% to 89%). None of
the eight vaccinated cases died.
Conclusions Preliminary evidence suggests some
protection from the 2008-9 trivalent inactivated vaccine
against pandemic influenza A/H1N1 2009, particularly
severe forms of the disease, diagnosed in a specialty
hospital during the influenza epidemic in Mexico City.
INTRODUCTION
From April to June 2009, reported confirmed cases of
influenzaduetothenovelinfluenzaA/H1N1virusled
the World Health Organization to raise the alert level
of influenza pandemic from phase 3 to phase 6. In less
than two months the spread of the virus worldwide
indicated the start of the 2009 influenza pandemic.
Upto6July2009,122countrieshadofficiallyreported
94512 laboratory confirmed cases.
1
The new virus may have started in Mexico and
southern California.
2 Between 1 March and 29 May
2009, the Mexican national system of surveillance
identified 41998 people with acute respiratory tract
disease, of whom 25127 (59.8%) were tested. Of
these, 5337 (21.2%) were identified as having the
novel A/H1N1 virus using real time reverse transcrip-
tasepolymerasechainreactionassay.By29May2009,
97 people had died.
3 The start of the outbreak was
marked by three separate events that occurred in
Mexico City, San Luis Potosi, in central Mexico, and
Mexicali, near the border with the United States; by
late April suspected clinical cases had been reported
in19ofthe32statesinMexico.
45Epidemiologicalevi-
denceindicated that the outbreak peaked nationally in
late April, although localised cases continue to be
identified.
3
The viral genomic sequence for several of the novel
A/H1N1strains,includingaMexicanisolate,hasbeen
made publicly available.
6 Given the new reassortant
nature of this virus—that is, unusual mixing of swine,
avian, and human influenza genetic sequences—the
available evidence, although incomplete, suggests
thatseasonalvaccineswillconferlittleornoprotection
against influenza A/H1N1.
7 Mexican guidelines
recommend vaccination with trivalent inactivated
influenza vaccine (virus strains A/Brisbane/59/2007
(H1N1)-like, A/Brisbane/10/2007 (H3N2)-like, and
B/Florida/4/2006-like antigen) for children aged
6-35 months, all adults aged more than 60, and indivi-
duals older than 35 monthswith conditions conferring
a higher risk of influenza related complications.
8 We
evaluated the association of 2008-9 seasonal trivalent
inactivated vaccine with cases of influenza A/H1N1 in
aspecialtyhospitalinMexicoCityduringtheinfluenza
epidemic.
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The National Instituteof RespiratoryDiseases is a 178
bedspecialtyhospitalthatprovidesoutpatientandhos-
pital care for uninsured people of low and medium
socioeconomic status living mostly in Mexico City
and its surrounding states—mainly the State of Mex-
ico. Although the institute is a specialty hospital, it
sometimes functions as a primary healthcare facility
because of the poor system for referral.
From 29 March to 20 May 2009 we carried out a
retrospective frequency matched case-control study.
Definition of cases and controls
Cases were people who had been admitted to hospital
or been seen as outpatients at the National Institute of
Respiratory Diseases and had a clinical diagnosis of
influenza and a respiratory tract specimen that tested
positive for novel influenza A/H1N1 by real time
reverse transcriptase polymerase chain reaction
assay.Weincludedinthestudyconsecutiveconfirmed
cases diagnosed during the study period. All the cases
lived in Mexico City or the State of Mexico.
Controls were people who lived in Mexico City or
the State of Mexico and had received medical care at
the National Institute of Respiratory Diseases for a
clinical diagnosis other than influenza during the
study period. We excluded patients with suspected
influenza or pneumonia or those who were prescribed
antiviral treatment.
Wefrequencymatchedthecasesandcontrolsbyage
(years, <5, 5-20, 21-40, 41-60, and >60) and socioeco-
nomic strata (low, medium, and high). Controls were
obtained by randomly sampling three times the num-
ber of cases within each category from a list, including
all patients who had received medical care at the hos-
pital during the study period. The patients recruited as
controls and those excluded were not significantly dif-
ferent for age, sex, or socioeconomic status.
Trained staff used a chart abstraction tool to collect
information from patients’ clinical files. Two of the
authors (LGG, RBS) checked the data to ensure qual-
ity, completeness, and validity. Information was col-
lected on age, sex, socioeconomic status, address,
telephone number, medical conditions, admission to
hospital, use of invasive mechanical ventilation, and
clinical outcome. Socioeconomic status was as
recorded in the clinical charts and based on the social
workers’evaluation,onthebasisofannualincomeand
formal education of each household member, number
in household, and characteristics of the household.
9
Forbothcasesandcontrolsweinvestigatedtrivalent
inactivatedinfluenzavaccinationforthe2008-9winter
season by face to face or telephone interview of the
patients or close relatives. Trained staff interviewed
patients using a set of prespecified items to ensure the
accuracy of vaccine status (date and place of vaccina-
tion, type of vaccine, other vaccines administered dur-
ing the same year). Interviewers were not blinded to
the status of cases or controls.
Laboratory confirmation of influenza A/H1N1 cases
Thecollectionofsamplesandlaboratoryconfirmation
has been described.
10 Briefly, nasopharyngeal speci-
mens were collected at admission using a swab and
bronchial aspirate samples were obtained after tra-
cheal intubation. Samples were placed in transport
mediumandkeptat2-4°C.Realtimereversetranscrip-
tasepolymerasechainreactionassaywascarriedoutat
the National Microbiology Laboratory in Winnipeg,
Canada; the Centers for Disease Control and Preven-
tion in Atlanta, USA; or the Instituto de Diagnostico y
Referencia Epidemiologicos, Mexico, in accordance
withpublishedguidelinesfromtheUSCentersforDis-
ease Control and Prevention.
11
Analysis
We used conditional logistic analyses to compare the
characteristics of the cases and controls and estimated
crude odds ratio and 95% confidence intervals when-
ever possible. To evaluate the efficiency of frequency
matching we compared the distribution of socioeco-
nomicstratabetweencasesandcontrols.Thebinomial
test was used to compare the prevalence of conditions
conferring a higher risk of influenza related complica-
tions between surviving and non-surviving cases. We
also used the binomial test to determine if the propor-
tionofpatientswhorequiredinvasivemechanicalven-
tilation or died among vaccinated and unvaccinated
cases differed significantly. We compared vaccination
status and the distribution of underlying conditions
between cases and controls by age group using condi-
tional logistic analyses and estimated crude odds ratio
and 95% confidence interval whenever possible.
After adjusting for sex and underlying conditions,
we modelled the association between influenza vacci-
nation and novel influenza A/H1N1 using conditional
logistic regression analysis. We analysed vaccination
statusasacategoricalmeasureofexposure,withvacci-
natedasreferent.Variableswereenteredintothemod-
els according to their significance in bivariate analysis
(P≤0.10) and their biological relevance. We also used
conditional regression analysis to model the associa-
tion between vaccine status and influenza A/H1N1
after adjusting for sex and underlying conditions for
each of the five age groups.
Theadjustedoddsratiowasusedtoestimatevaccine
effectiveness using the formula (1–adjusted odds
ratio)×100, as recommended in a previous study.
12
We estimated the power of the study on the basis of
the design, α=0.05, number of cases, number of con-
trols per case, observed frequency of vaccination
among controls, observed correlation coefficient, and
observed odds ratio.
Sensitivity analysis
We used conditional regression analysis to model the
association between vaccination and influenza
A/H1N1 and estimated vaccine effectiveness by
including only cases and controls who had been
admittedtohospital.Wealsomodelledtheassociation
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conditional regression analysis adjusting for sex in the
subset of patients without underlying conditions. We
used Stata 9.0.
RESULTS
Overall, 60 confirmed cases of influenza A/H1N1 and
180 controls were identified. The controls were
admitted to the outpatient clinic or to hospital for a
total of 270 diagnoses (table 1): four patients had four
diagnoses,13hadthree,52hadtwo,andtheremainder
(n=111) had one. The 10 most common reasons for
admission were elective ear, nose, or throat surgery;
asthma; obstructive sleep apnoea; chronic obstructive
pulmonary disease; gastro-oesophageal reflux; tuber-
culosis; HIV/AIDS; arterial hypertension; interstitial
pneumopathy; and diabetes.
Controls who had been vaccinated against 2008-9
seasonal influenza were significantly more likely than
cases to refer (table 2). Most of the cases (n=38, 63%)
were aged 21-60 years. Frequency matching ensured
thatthecasesandcontrolswerebalancedforsocioeco-
nomic status (table 2). Cases and controls were also
similar for sex.
The cases had more severe clinical manifestations
than the controls; they were more likely to be admitted
to hospital, undergo invasive mechanical ventilation,
and die. Most of the cases had been previously healthy
(n=45, 75%). Overall, the controls were significantly
morelikelythanthecasestohaveunderlyingconditions
conferring a higher risk of influenza related complica-
tions (table 2). With the exception of diabetes, which
was three times more prevalent among cases than
among controls (7 (12%) v 6( 3 % ) ,P =0.02), compared
with cases the prevalence of other conditions among
controls was higher or not significantly different.
The prevalence of underlying conditions conferring
a higher risk of influenza related complications was
similar among surviving and non-surviving cases
(10/42 (24%) v 5/18 (28%), P=0.75). Conditions
among the 10 surviving cases included chronic renal
insufficiency, obesity, congenital thoracic deformity,
and chronic obstructive pulmonary disease (one
each);asthma(n=2);diabetes(n=3); anddiabetes, obe-
sity, and chronic renal insufficiency (n=1). Conditions
among the five cases who died included chronic
obstructive pulmonary disease, obstructive sleep
apnoea, and HIV/AIDS (one each); diabetes and pul-
monary arterial hypertension (n=1); and diabetes and
obstructive sleep apnoea (n=1).
The proportion of patients who died among vacci-
nated cases was significantly lower than among unvac-
cinated cases (0/8 (0%) v 18/52 (35%), P=0.047). The
proportion of patients requiring invasive mechanical
ventilation was also lower among vaccinated cases
than among unvaccinated cases, although this was
not significant (1/8 (13%) v 25/52 (48%), P=0.058).
Table 3showsthenumberofcasesandcontrolsand
information on vaccination status and prevalence of
underlying conditions by age group. With the excep-
tion of the age group 5-20 years, the crude odds ratio
for vaccination during the previous season showed a
protective effect for all age groups, although this was
not statistically significant. The prevalence of underly-
ing conditions conferring a higher risk of influenza
related complications was significantly greater among
controlsaged<5,41-60,andmorethan60.Whenindi-
vidual conditions were analysed by age group, asthma
was significantly more prevalent among controls aged
5-20 and 21-40, whereas diabetes was significantly
more prevalent among cases aged 21-40.
In the multivariate model, vaccination status and
underlying conditions were independently associated
with influenza A/H1N1 (table 4). When the associa-
tion of influenza A/H1N1 with vaccine status for each
age group was modelled, the adjusted odds ratio con-
tinued to show a protective effect, although this was
statistically significant only for the age group 41-60
(table 3).Vaccineeffectivenessagainstlaboratorycon-
firmed cases of influenza A/H1N1 was 73% (95% con-
fidence interval 34% to 89%).
Table 1 |Admission diagnoses of 180 controls*
Diagnosis No(%)ofcontrols(n=180))
Elective ear, nose, or throat surgery 73 (41)
Asthma 51 (28)
Obstructive sleep apnoea 22 (12)
Chronic obstructive pulmonary disease 16 (9)
Gastro-oesophageal reflux 11 (6)
Tuberculosis 11 (6)
HIV/AIDS 10 (6)
Arterial hypertension 8 (4)
Interstitial pneumopathy 7 (4)
Diabetes 6 (3)
Lung cancer 5 (3)
Chronic haemoptysis 5 (3)
Chronic heart disease 4 (2)
Pleural disease 4 (2)
Obesity 4 (2)
Bronchiectasis 3 (2)
Systemic autoimmune disease 3 (2)
Thoracic surgery 3 (2)
Pulmonary arterial hypertension 3 (2)
Pneumocystis jirovecii pneumonia 3 (2)
Congenital thoracic deformity 2 (1)
Tracheal stenosis 2 (1)
Chronic renal insufficiency 2 (1)
Pulmonary nodule 2 (1)
Pulmonary sequestration 1 (0.6)
Elective tracheostomy 1 (0.6)
Pulmonary embolism 1 (0.6)
Bronchiolitis 1 (0.6)
Hepatic cirrhosis 1 (0.6)
Dermatitis 1 (0.6)
Tobacco addiction 3 (2)
Pregnancy 1 (0.6)
*Four patients had four diagnoses, 13 had three, 52 had two, and the
remainder (n=111) had one.
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Weestimatedthepowerofthestudytobe88%,assum-
ing a type I error probability of 0.05, 60 cases, three
controls for each case, 29% prevalence of vaccination
inthe controlgroup,a correlationcoefficientforexpo-
sure between matched cases and controls of 0.21, and
an adjusted odds ratio of 0.27.
Sensitivity analysis
When only the subset of cases (n=59) and controls
(n=61) admitted to hospital was analysed the associa-
tion between confirmed cases of influenza A/H1N1
and vaccination status was significant (table 4). Vac-
cine effectiveness was 77% (22% to 93%). When the
association between influenza A/H1N1 cases and vac-
cinationstatuswasmodelledamongthesubsetofcases
(n=45)andcontrols(n-60)withouthighriskunderlying
conditions, it continued to be significant (table 4). The
estimatedvaccineeffectivenessforthissubsetwas86%
(50% to 96%)
DISCUSSION
The influenza vaccine used for the winter of 2008-9 in
the northern hemisphere contained the trivalent vac-
cine virus strains A/Brisbane/59/2007 (H1N1)-like,
A/Brisbane/10/2007 (H3N2)-like, and B/Florida/4/
2006-like antigen. The Mexican Public Health Institu-
tionsprovidedtrivalentinactivatedinfluenzavaccineas
partofthe national vaccination programme. Thisstudy
presents clinical data suggesting that this vaccine may
provide some protection against influenza A/H1N1,
diagnosed in a specialty hospital during the epidemic
of the novel influenza virus in Mexico. Moreover, that
noneofthevaccinatedcasesofinfluenzaA/H1N1died,
indicatesthatseasonalvaccinationmightprotectagainst
the most severe forms of the disease.
These results are to be considered cautiously and in
no way indicate that seasonal vaccine should replace
vaccination against pandemic influenza A/H1N1
2009. Our data support the hypothesis that partial pro-
tection provided by the seasonal vaccine may be
explained by the boosting of existing antibodies that
were elicited by previous exposure, through either
infection or vaccination, to an influenza A/H1N1 virus
geneticallyandantigenicallymorecloselyrelatedtothe
novel influenza virus than contemporary seasonal
H1N1 strains. In fact, the impact of seasonal vaccine
over protection against pandemic influenza induced
by pandemic influenza vaccine is presently being stu-
died in different clinical trials by the National Institutes
ofHealthandotheragencies(http://clinicaltrials.gov/).
Previous studies focusing on seasonal vaccine offer-
ing cross protection against antigenically differing
influenza strains occurring in epidemics indicate
some level of protection. One study showed a small
boost in cross reactive antibodies (measured by
hemagglutination inhibition analysis) against
A/Swine/Iowa 1930 A/H1N1 and 1918 HA/NA
recombinant virus among 15 volunteers vaccinated
with A/New Caledonia/20/1999 A/H1N1.
13 Cross
protection against the 1968/1969 pandemic influenza
virus provided by the 1967 vaccines was evaluated
during an outbreak among military staff. Polyvalent
vaccine, 1967 formula, contributed towards prevent-
ing disease in those who did not receive the pandemic
vaccine.
14 Duringthe present 2009 epidemic, the Cen-
tersforDiseaseControlstudiedserumcrossprotection
afforded by seasonal vaccines against the novel influ-
enza A/H1N1.
15 Using stored serum specimens from
previous vaccine studies, the researchers assessed the
level of cross reactive antibody to the novel influenza
A/H1N1 virus in cohortsof children aged6 months to
9 years (n=28), adults aged 18-59 (n=30), and adults
aged more than 60 (n=42) before and after vaccination
with the 2005-6, 2006-7, 2007-8, and 2008-9 seasonal
vaccinesagainstinfluenza.Resultssuggestedthatsome
immunity to the novel strain may exist among adults,
especially among those aged more than 60. After vac-
cinationinadults,7%aged18-40,25%aged18-64,and
43% aged more than 60 had microneutralisation titres
of 160 or more to the new virus, which was the esti-
mated protective titre.
Table 2 |Personal and clinical characteristics of influenza A/H1N1 cases and controls. Values
are numbers (percentages) unless stated otherwise
Characteristics
Cases
(n=60)
Controls
(n=180)
Crude odds ratio
(95% CI)* P value
Vaccinated 8 (13) 53 (29) 0.344 (0.149 to 0.793) 0.012
Men 32 (53) 106 (59) 0.797 (0.442 to 1.436) 0.5
Low socioeconomic status 34 (57) 105 (58) — 0.8†
Age group (years):
<5 10 (17) 30 (17) ——
5-20 7 (12) 21 (12) ——
21-40 18 (30) 54 (30) ——
41-60 20 (33) 60 (33) ——
>60 5 (8) 15 (8) ——
Admitted to hospital 59 (98) 61 (34) 129 (17 to 968) <0.001
Invasive mechanical ventilation 26 (43) 4 (2) 37.28 (11.88 to 117.02) <0.001
Deaths 18 (30) 2 (1) — <0.001†
Underlying conditions‡: 15 (25) 120 (67) 0.17 (0.09 to 0.32) <0.001
Asthma 2 (3) 51 (28) 0.07 (0.02 to 0.32) 0.001
Obstructive sleep apnoea 2 (3) 22 (12) 0.24 (0.05 to 1.06) 0.06
Chronic obstructive
pulmonary disease
1 (2) 16 (9) 0.14 (0.02 to 1.19) 0.07
Diabetes 7 (12) 6 (3) 3.90 (1.24 to 12.28) 0.02
Gastro-oesophageal reflux 0 11 (6) — 0.07†
HIV/AIDS 1 (2) 10 (6) 0.28 (0.03 to 2.25) 0.2
Interstitial pneumopathy 0 (0) 7 (4) — 0.2†
Obesity 2 (3) 4 (2) 1.53 (0.26 to 8.79) 0.6
Lung cancer 0 (0) 5 (3) — 0.3†
Chronic heart disease 0 (0) 4 (2) — 0.5†
Chronic renal insufficiency 2 (3) 2 (1) 3.00 (0.42 to 21.29) 0.2
Other§ 2 (3) 14 (8)
*Calculated using conditional logistic regression.
†Fisher’s exact test.
‡Medical conditions conferring a higher risk of influenza related complications. Three controls had three
conditions; 26 controls two conditions; one case diabetes, chronic renal insufficiency, and obesity; and one
case diabetes and obstructive sleep apnoea.
§Bronchiectasis (three controls), congenital thoracic deformity (one case, two controls), tracheal stenosis (two
controls), pulmonary arterial hypertension (one case, three controls), systemic autoimmune disease (three
controls), elective tracheostomy (one control).
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Characteristics by age group No (%) cases No (%) controls Crude odds ratio (95% CI)* P value Adjusted odds ratio (95% CI)† P value
<5 years (10 cases, 30 controls)
Vaccinated 4 (40.0) 16 (53.3) 0.59 (0.14 to 2.49) 0.5 0.4 (0.06 to 3.10) 0.4
Underlying conditions‡: 2 (20.0) 26 (86.7) 0.05 (0.01 to 0.29) 0.001 ——
Asthma 1 (10.0) 13 (43.3) 0.16 (0.02 to 1.36) 0.09 ——
Obstructive sleep apnoea 1 (10.0) 10 (33.3) 0.23 (0.03 to 2.05) 0.2 ——
Gastro-oesophageal reflux 0 4 (13.3) — 0.6§ ——
Interstitial pneumopathy 0 1 (3.3) — 1§ ——
Chronic heart disease 0 1 (3.3) — 1§ ——
5-20 years (7 cases, 21 controls)
Vaccinated 1 (14.3) 3 (14.3) 1 (0.08 to 12.85) 1 0.5 (0.02 to 10.95) 0.7
Underlying conditions*: 2 (28.6) 15 (71.4) 0.19 (0.03 to 1.13) 0.07 ——
Asthma 1 (14.3) 14 (66.7) 0.1 (0.01 to 0.92) 0.04 ——
Chronic heart disease 0 1 (4.8) — 1§ ——
Chronic renal insufficiency 1 (14.3) 0 — 0.3§ ——
Other 0 1 (4.8) — 1§ ——
21-40 years (18 cases, 54 controls)
Vaccinated 1 (5.6) 12 (22.2) 0.21 (0.03 to 1.73) 0.1 0.25 (0.03 to 2.19) 0.2
Underlying conditions*: 6 (33.3) 31 (57.4) 0.37 (0.12 to 1.15) 0.1 ——
Asthma 0 14 (25.9) — 0.02§ ——
Obstructive sleep apnoea 0 5 (9.3) — 0.3§ ——
Chronic obstructive pulmonary disease 0 1 (1.9) — 1§ ——
Diabetes 4 (22.2) 0 — 0.003§ ——
Gastro-oesophageal reflux 0 3 (5.6) — 0.6§ ——
HIV/AIDS 1 (5.6) 8 (14.8) 0.35 (0.04 to 2.93) 0.3 ——
Interstitial pneumopathy 0 1 (1.9) — 1§ ——
Obesity 2 (11.1) 2 (3.7) 3.32 (0.42 to 26.16) 0.3 ——
Lung cancer 0 1 (1.9) — 1§ ——
Chronic renal insufficiency 1 (5.6) 0 — 0.3§ ——
Other 1 (5.6) 6 (11.1) 0.48 (0.05 to 4.18) 0.5 ——
41-60 years (20 cases, 60 controls)
Vaccinated 1 (5.0) 18 (30.0) 0.13 (0.01 to 1.00) 0.05 0.05 (0.006 to 0.53) 0.01
Underlying conditions*: 4 (20.0) 36 (60.0) 0.17 (0.05 to 0.57) 0.004 ——
Asthma 0 10 (16.7) — 0.06§ ——
Obstructive sleep apnoea 1 (5.0) 5 (8.3) 0.59 (0.065 to 5.23) 0.6 ——
Chronic obstructive pulmonary disease 1 (5.0) 8 (13.3) 0.35 (0.04 to 2.92) 0.3 ——
Diabetes 3 (15.0) 5 (8.3) 1.92 (0.42 to 8.77) 0.4 ——
Gastro-oesophageal reflux 0 3 (5.0) — 0.6§ ——
HIV/AIDS 0 2 (3.3) — 1§ ——
Interstitial pneumopathy 0 3 (5.0) — 0.6§ ——
Obesity 0 2 (3.3) — 1§ ——
Lung cancer 0 3 (5.0) — 0.6§ ——
Chronic heart disease 0 2 (3.3) — 1§ ——
Chronic renal insufficiency 0 1 (1.7) — 1§ ——
Other 0 5 (8.3) — 0.3§ ——
>60 years (5 cases, 15 controls)
Vaccinated 1 (20.0) 4 (26.7) 0.65 (0.05 to 8.97) 0.7 0.37 (0.01 to 11.64) 0.6
Underlying conditions*: 1 (20.0) 12 (80.0) 0.08 (0.01 to 0.87) 0.04 ——
Obstructive sleep apnoea 0 2 (13.3) — 1§ ——
Chronic obstructive pulmonary disease 0 7 (46.7) — 0.1§ ——
Diabetes 0 1 (6.7) — 1§ ——
Gastro-oesophageal reflux 0 1 (6.7) — 1§ ——
Interstitial pneumopathy 0 2 (13.3) — 1§ ——
Lung cancer 0 1 (6.7) — 1§ ——
Chronic renal insufficiency 0 1 (6.7) — 1§ ——
Other 1 (20.0) 1 (6.7) 3.46 (0.18 to 67.64) 0.4 ——
*Calculated using conditional logistic regression.
†Conditional logistic regression used to control for sex and underlying medical conditions conferring a higher risk for influenza complications.
‡Medical conditions conferring a higher risk of influenza related complications.
§Fisher’s exact test.
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16 studies indicate protection
ranging from 18.8% to 90% among children and
healthy young adults
17-22 against severe outcomes
when seasonal influenza vaccine strains are not anti-
genically well matched to circulating endemic strains.
Vaccine effectiveness varies considerably depending
on study population (age, associated diseases, number
of vaccine doses, and access to vaccine), specificity of
outcome (medically attended acute respiratory tract
disease, laboratory confirmed influenza, pneumonia
associatedadmissionstohospitalordeaths,orserocon-
version to circulating influenza virus strains), and cir-
culating strains. In this study we dealt with some of
these confounders by frequency matching for age and
socioeconomic status and by adjusting for sex and
chronic underlying conditions in the analysis.
Influenza A/H1N1 viruses circulated in humans
from 1918 until 1957, when they were replaced by
the A/H2N2 virus; they reappeared in 1977.
23 Notice-
ably, the similarity of A/H1N1 viruses in 1977 to
viruses circulating in 1950 explained substantial
immunity among adults aged 27 or more who been
exposed to these viruses and illnesses mainly in the
younger population.
24 Thereafter, A/H1N1 virus did
not replace the preceding H3N2 subtype. Therefore
the two influenza A subtypes, H1N1 and H3N2, have
cocirculated with influenza B viruses since 1977, and
current trivalent inactivated vaccines contain repre-
sentatives of each A subtype and B virus. Antigens on
the human A/H1N1 virus have evolved considerably
since 1972, leading to several changes in the A/H1N1
component of the vaccine.
24 The novel A/H1N1 2009
virus contains a unique combination of gene segments
from both North American and Eurasian swine
lineages.
25 Using post-infection ferret antisera tested
by haemagglutination inhibition assay, researchers
havefoundthisvirustobeantigenicallysimilartoclas-
sicalswineA/H1N1virusaswellastoNorthAmerican
lineage triple reassortant A/H1N1 viruses that have
circulated in swine since the late 1990s in the United
States and that have occasionally infected humans.
25
Thelackofsimilaritiesbetweenthisvirusanditsclosest
relatives emphasises the lack of surveillance in swine
populationsthatmayharbourinfluenzaviruswithpan-
demic potential and the possibility of its unidentified
transmission to humans.
Limitations of the study
Our study has several limitations, inherent to retro-
spective studies. The distribution and prevalence of
diagnoses among controls on admission reflects the
kindofpatientswhoareadmittedtotheNationalInsti-
tute of Respiratory Diseases, a centre specialising in
respiratory diseases and not a general hospital. There-
fore the prevalence of chronic conditions conferring a
higherriskofinfluenzarelatedcomplicationswashigh
among the controls and thus their chance of having
beenvaccinatedwashigherthaninthegeneralpopula-
tion. Among our control population the frequency of
influenza vaccination during the previous season by
age group (64% for children aged 6-35 months, 38%
for children aged 3-9 years, and 19% for adults older
than50)waslowerthanvaccinationcoveragereported
nationally (72%, 64%, and 78%, respectively). Since
national estimates for vaccination coverage were not
available for young people and adults aged 10-49, we
modelled the association between vaccine status and
influenzaA/H1N1foreachagegroup.Resultsshowed
that the association between vaccine status and influ-
enza A/H1N1 continued to be protective, although
this was statistically significant only for those aged
41-60. Wide confidence intervals were probably due
to small sample sizes.
We consider that cases and controls originated from
the same source population as cases of influenza
A/HINI and controls were drawn from the same geo-
graphical area—Mexico City and the State of Mexico,
which had the majority of notifications for influenza
during the study period.
3 Therefore the controls had
thesameprobabilityofbeingexposedtoinfectiveindi-
viduals as cases. Frequency matching allowed us to
obtain a similar distribution of potential confounders
(ageandsocioeconomicstatus)betweencasesandcon-
trols.Socioeconomiclevelmayserveasanindicatorof
access to health services (as has been shown by pre-
vious studies).
2627
Most of the cases of influenza A/H1N1 had severe
disease, which is understandable given that the
National Institute of Respiratory Diseases is a hospital
specialising in respiratory diseases and that surveil-
lance was focused on more severe cases. Therefore
we focusedoncaseswithmoresevereclinicalmanifes-
tations,estimatedtobe6%ofthetotalnumberofcases
in Mexico.
28 All but one of the cases of influenza
A/H1N1 were admitted to hospital compared with
34% of the controls. We consider this comparison to
be a valid one as most of the transmission of influenza
occurred out of the hospital—that is, was not hospital
acquired. Sensitivity analyses showed that the vaccine
was effective for the subset of cases and controls who
were admitted to hospital and for patients with no
underlying conditions conferring a higher risk of
Table 4 |Variables associated with influenza A/H1N1, by conditional logistic regression
analysis
Characteristic
Adjusted odds ratio
(95% CI) P value
Participants (60 cases, 180 controls):
Vaccinated v unvaccinated (2008-9 winter season) 0.27 (0.11 to 0.66) 0.004
Men 0.72 (0.37 to 1.37) 0.3
Underlying conditions* 0.15 (0.08 to 0.30) <0.001
Participants admitted to hospital (59 cases, 61 controls):
Vaccinated v unvaccinated (2008-9 winter season) 0.23 (0.07 to 0.78) 0.018
Men 0.85 (0.37 to 1.97) 0.7
Underlying conditions* 0.20 (0.09 to 0.45) <0.001
Participants with no underlying conditions* (45 cases, 60 controls):
Vaccinated v unvaccinated (2008-9 winter season) 0.14 (0.04 to 0.50) 0.003
Men 0.73 (0.31 to 1.73) 0.479
*Medical conditions conferring a higher risk of influenza related complications.
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laboratory confirmed cases of influenza A/H1N1 to
increasethespecificityofourcasedefinition.Similarly,
we excluded cases with suspected influenza or pneu-
monia and patients receiving antivirals from our con-
trol group. Aswe were unable tomatch for underlying
conditions conferringa higher risk of influenza related
complications, we adjusted for this variable in the ana-
lyses.Influenzavaccinationduringthepreviouswinter
was investigated by trained staff using a standardised
format to reduce the bias associated with self reported
vaccinestatus;however,interviewerswerenotblinded
to the status of cases and controls. Vaccine status was
not, however, recorded on the medical charts so it was
not possible to check the self reported information.
Conclusions
Our study provides preliminary evidence suggesting
some protection from the 2008-9 trivalent inactivated
vaccine against pandemic influenza A/H1N1 2009,
particularly severe forms of the disease, diagnosed in
a specialty hospital during the epidemic in Mexico
City. Notwithstanding this contribution to protection,
a specific vaccine against A/H1N1 2009 is crucial. In
the coming months, seasonal and pandemic influenza
vaccines will become available around the world.
29
Prospective studies need to investigate the impact of
seasonalvaccinationovertheimmunologicalresponse
elicited by pandemic A/H1N1 2009 vaccine.
Although this study provides preliminary evidence
of a protective effect of seasonal vaccination against
influenza A/H1N1 virus, it is prone to limitations due
tosmallsamplesizeandtheretrospectivestudydesign.
Thereforetheestimatesforvaccineeffectivenesscould
be inflated owing to a high prevalence of chronic con-
ditions and vaccination in our control population.
Similar studies in other settings are needed to confirm
or refute our results.
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